Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (187)	9/7/1998 11:26:00 AM
From: Thomas Kirwin	Respond to of 422

The Company One Keeps Mason, Immucor has taken great pains to network with individuals as well as other companies. The addition of Joseph Rosen, President of Sera-Tec Biologicals, to the Company's Board of Directors will help Immucor gain access to 53 plasma collection centers in the United States. Sera-Tec is based in New Jersey and processes about one million samples each year. Another fine strategic networking partnership was solidified when Immucor selected Dennis M. Smith, Jr. as a Director on 04/17/98. Dr. Smith is the Chairman of the Section of Pathology and the Director of Laboratories at Columbia Memorial Hospital in Jacksonville, FL. In addition to these duties, Dr. Smith is a member of the Board of Directors of Medical Equity Partners, Jacksonville, FL, Vice President of Laboratory Physicians, St. Petersburg, FL and Managing Director, Jacksonville Division of AmeriPath, Inc. "His recent experience as Past President of the American Association of Blood Banks and his current position on the Board of Directors of the National Blood Foundation provide Dr. Smith with tremendous knowledge of the issues facing our industry. This insight will be invaluable as Immucor develops new strategic initiatives to meet the needs of our industry." Joseph Rosen immucor.com Dennis M. Smith, Jr. immucor.com IMHO - I don't think that the I-TRAC system developed through the cooperative venture of Immucor Inc, Sanguin International Ltd, and Healthcare-ID Inc will be the last. Acquisitions, mergers and strategic alliances will help Immucor add new and innovative medical devices to its growing product line. Regards, Tom